Capstone Investment Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $39.4M | Sell |
181,200
-64,600
| -26% | -$14.3M | 0.07% | 111 |
|
|
2025
Q4 | $56.2M | Sell |
245,800
-79,600
| -24% | -$18.1M | 0.11% | 87 |
|
|
2025
Q3 | $75.3M | Buy |
325,400
+101,400
| +45% | +$20.6M | 0.14% | 72 |
|
|
2025
Q2 | $41.6M | Sell |
224,000
-163,500
| -42% | -$30.4M | 0.1% | 81 |
|
|
2025
Q1 | $81.2M | Sell |
387,500
-91,200
| -19% | -$17.7M | 0.21% | 50 |
|
|
2024
Q4 | $85.1M | Buy |
478,700
+223,600
| +88% | +$41.1M | 0.21% | 61 |
|
|
2024
Q3 | $50.4M | Sell |
255,100
-6,100
| -2% | -$1.14M | 0.15% | 81 |
|
|
2024
Q2 | $44.8M | Sell |
261,200
-10,500
| -4% | -$1.74M | 0.14% | 95 |
|
|
2024
Q1 | $49.5M | Sell |
271,700
-109,400
| -29% | -$18.9M | 0.18% | 82 |
|
|
2023
Q4 | $59.1M | Buy |
381,100
+49,600
| +15% | +$7.23M | 0.18% | 85 |
|
|
2023
Q3 | $49.4M | Buy |
331,500
+129,700
| +64% | +$19M | 0.22% | 53 |
|
|
2023
Q2 | $27.2M | Buy |
201,800
+15,800
| +8% | +$2.32M | 0.13% | 103 |
|
|
2023
Q1 | $29.6M | Sell |
186,000
-1,700
| -0.9% | -$260K | 0.15% | 83 |
|
|
2022
Q4 | $30.3M | Buy |
187,700
+3,500
| +2% | +$537K | 0.22% | 65 |
|
|
2022
Q3 | $24.7M | Sell |
184,200
-58,900
| -24% | -$8.45M | 0.15% | 79 |
|
|
2022
Q2 | $37.2M | Sell |
243,100
-665,200
| -73% | -$102M | 0.18% | 71 |
|
|
2022
Q1 | $147M | Sell |
908,300
-890,700
| -50% | -$129M | 0.4% | 27 |
|
|
2021
Q4 | $244M | Buy |
1,799,000
+496,200
| +38% | +$58.6M | 0.41% | 43 |
|
|
2021
Q3 | $141M | Sell |
1,302,800
-89,600
| -6% | -$10.2M | 0.28% | 67 |
|
|
2021
Q2 | $157M | Buy |
1,392,400
+214,600
| +18% | +$24.2M | 0.36% | 54 |
|
|
2021
Q1 | $127M | Buy |
1,177,800
+262,800
| +29% | +$28.1M | 0.38% | 48 |
|
|
2020
Q4 | $98M | Buy |
915,000
+445,800
| +95% | +$42.8M | 0.33% | 50 |
|
|
2020
Q3 | $41.1M | Sell |
469,200
-66,000
| -12% | -$6.21M | 0.21% | 85 |
|
|
2020
Q2 | $52.5M | Buy |
535,200
+442,100
| +475% | +$38.9M | 0.35% | 40 |
|
|
2020
Q1 | $7.09M | Sell |
93,100
-563,800
| -86% | -$48M | 0.11% | 192 |
|
|
2019
Q4 | $58.2M | Buy |
656,900
+213,000
| +48% | +$17.7M | 0.31% | 64 |
|
|
2019
Q3 | $33.6M | Buy |
443,900
+120,100
| +37% | +$8.23M | 0.23% | 92 |
|
|
2019
Q2 | $23.5M | Buy |
323,800
+108,400
| +50% | +$8.52M | 0.17% | 134 |
|
|
2019
Q1 | $17.4M | Buy |
215,400
+63,500
| +42% | +$5.19M | 0.16% | 139 |
|
|
2018
Q4 | $14M | Buy |
151,900
+31,600
| +26% | +$2.78M | 0.17% | 93 |
|
|
2018
Q3 | $11.4M | Buy |
120,300
+86,200
| +253% | +$8.17M | 0.13% | 123 |
|
|
2018
Q2 | $3.16M | Buy |
+34,100
| New | +$3.33M | 0.05% | 207 |
|
|
2017
Q2 | – | Sell |
-12,500
| Closed | -$813K | – | 612 |
|
|
2017
Q1 | $813K | Sell |
12,500
-3,900
| -24% | -$245K | 0.02% | 477 |
|
|
2016
Q4 | $1.03M | Buy |
+16,400
| New | +$1M | 0.03% | 411 |
|
|
2014
Q4 | – | Sell |
-100,000
| Closed | -$5.78M | – | 322 |
|
|
2014
Q3 | $5.78M | Buy |
+100,000
| New | +$5.55M | 0.07% | 204 |
|
Other funds holding ABBV
VCM
VPM
Capstone Investment Advisors's ABBV Position: Q1 2026 in Review
Capstone Investment Advisors reduced its AbbVie (ABBV) stake by 9% in Q1 2026, selling an estimated $105K and leaving 4,761 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #854.
Capstone Investment Advisors first reported a position in ABBV in Q4 2015 and has held it in 28 quarters since. The position peaked at $8.41M in Q3 2021. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Capstone Investment Advisors held 4,761 shares of AbbVie worth $1.04M as of Q1 2026.
- Capstone Investment Advisors sold 472 AbbVie shares in Q1 2026, an estimated $105K.
- AbbVie made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #854 holding.
- Capstone Investment Advisors first reported a position in AbbVie in Q4 2015 and has held it in 28 quarters since.
- Capstone Investment Advisors's AbbVie position peaked at $8.41M in Q3 2021.
- 4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.